Adalimumab treatment for severe recalcitrant chronic plaque psoriasis.
AffiliationDepartment of Dermatology, St Vincent's University Hospital, Dublin, Ireland., firstname.lastname@example.org
Antibodies, Monoclonal/administration & dosage/adverse effects/*therapeutic use
Antibodies, Monoclonal, Humanized
Dermatologic Agents/administration & dosage/adverse effects/*therapeutic use
Drug Administration Schedule
Severity of Illness Index
MetadataShow full item record
CitationClin Exp Dermatol. 2009 Oct;34(7):784-8. Epub 2009 Apr 27.
JournalClinical and experimental dermatology
AbstractAIM: To assess the efficacy and safety profile of adalimumab in patients with severe, recalcitrant chronic plaque psoriasis, and to assess short-term overlapping of other systemic treatment with adalimumab to prevent flaring of disease. METHODS: This was a retrospective study comprising 39 patients with chronic plaque psoriasis treated with adalimumab between October 2005 and January 2008. All had failed treatment with other systemic agents, including biological therapies in 59% of patients. Patients were started on adalimumab 40 mg weekly or fortnightly, as clinically indicated. Severity of psoriasis was assessed by the Psoriasis Area and Severity Index (PASI). Therapeutic response was assessed by 75% improvement on PASI (PASI 75). All adverse events were recorded. RESULTS: Results were analysed separately for those treated with adalimumab only and those on combination treatment. PASI 75 was achieved in 38% (8 of 21 patients at week 16), 62% (13 of 21 patients) at week 24, 69% (9 of 13 patients) at week 48% and 71% (5 of 7 patients) at week 72 in the adalimumab-only group, compared with 56% (5 of 9 patients) at week 16, 50% (4 of 8 patients) at week 24, 80% (4 of 5 patients) at week 48% and 67% (2 of 3 patients) at week 72 in the combined group. Of the 39 patients, 15 (38%) achieved a PASI of 0 at some point in their treatment. Adalimumab was well tolerated; 38% of patients experienced side-effects, which were generally mild. CONCLUSION: Adalimumab was effective in a group of patients with psoriasis refractory to other systemic therapies, including biological treatments, and was well tolerated.
- Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
- Authors: Van Lümig PP, Lecluse LL, Driessen RJ, Spuls PI, Boezeman JB, van de Kerkhof PC, De Jong EM
- Issue date: 2010 Oct
- Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
- Authors: Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM
- Issue date: 2010 Sep
- Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
- Authors: Barker J, Hoffmann M, Wozel G, Ortonne JP, Zheng H, van Hoogstraten H, Reich K
- Issue date: 2011 Nov
- Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
- Authors: Papoutsaki M, Chimenti MS, Costanzo A, Talamonti M, Zangrilli A, Giunta A, Bianchi L, Chimenti S
- Issue date: 2007 Aug
- Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.
- Authors: Sola-Ortigosa J, Sánchez-Regaña M, Umbert-Millet P
- Issue date: 2012 Jun